Pharmacokinetics of low molecular weight heparin in patients with malignant tumors.


Cancer patients have an increased risk for venous thromboembolism (VTE). Low molecular weight heparin (LMWH) is the mainstay of VTE treatment in these patients. Heparanase, which degrades heparin and LMWH, is an enzyme secreted from a variety of malignant tumors. The objective of this study was to elucidate the pharmacokinetics of LMWH in patients with… (More)
DOI: 10.1097/CAD.0000000000000176


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics